Imaging Center COE

PSMA Imaging and Theranostics: Future Impact to Patient Management– Robert Flavell

(Length of presentation: 30 min) In an interview with Phil Koo, Robert Flavell describes diagnostic and therapeutic applications of new agents in the management of patients with prostate cancer with initial high-risk diagnosis and biochemical recurrence. Biographies: Robert R. Flavell, MD, Ph.D., Assistant Professor in Residence Department of Radiology, Section of Nuclear Medicine, University of C...

Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro

(Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...

Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo

(Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...

The Incredible Shrinking nmCRPC - Phillip Koo

(Length of Presentation: 12 min) Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient. His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He d...

The Utility of PSMA PET In Prostate Cancer Management- Stefano Fanti

(Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...

18F-FDG PET/CT Diagnostic Value in Recurrent Germinal Tumor Carcinoma

(Length of discussion - 8 minutes) Approximately 25% of testicular cancer patients present with advanced stage disease. Once chemotherapy is administered, radiologically-detectable residual masses are found in about 60% of these patients, making it difficult for a clinician to diagnose residual disease versus fibrosis or necrosis. Long-term survivable rates for these patients is generally favorabl...

Whole Body MRI Scanning and Disease Progression - Anwar Padhani

Professor Anwar Padhani discusses the value of whole body MRI scanning in diagnosing disease progression at the Radiological Society of North America (RSNA) 2017 conference. Dr. Padhani discusses the biggest advantage of using whole body MRI scanning versus bone or CT scans, which is the ability to detect metastatic disease in bone. Whole body MRI scans are also accurate in detecting castrate-resi...

The Past, Present, and Future Approaches to Prostate Biopsies - Baris Turkbey

Dr. Baris Turkbey, Associate Research Physician of the Molecular Imaging Program at the National Cancer Institute, shares the past, present, and future approaches to prostate biopsies. Dr. Turkbey states that TRUS (Transrectal Ultrasound aka Systemic) biopsies have been the “standard of care” after PSA elevation for the past 25 years. However, prostate imaging is not always preceding biopsy. MRI p...

Seeking a Diagnosis with a Rising PSA - Jelle Barentsz

(Length of discussion - 9 minutes) Dr. Jelle Barentsz provides his perspective on treating a patient with a rising PSA and is seeking diagnosis options. During this discussion held at the Radiological Society of North America (RSNA) 2017 conference, he shares that he would not recommend a 12-core systematic biopsy because it is not targeted. 40% of patients with a trans-rectal ultrasound guided (T...

18F-Fluciclovine PET/CT Scanning in High Risk Primary Prostate Carcinoma - Trond Bogsrud

18F-Fluciclovine PET/CT Scanning in Patients With High Risk Primary Prostate Carcinoma - Trond Bogsrud (Length of discussion - 10 minutes) Dr. Trond Bogsrud discusses the performance of the investigational amino acid PET tracer fluciclovine F18 compared to histopathology which was retrospectively evaluated in patients with high risk primary prostate carcinoma to investigate whether fluciclovine F1...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.